Coronary/Structural Heart

Tris Pharma and Athena Bioscience Announce Exclusive License Agreement to Commercialize Near-to-Market Long-Acting Antihypertensive Product in the U.S.

MONMOUTH JUNCTION, N.J. and ATHENS, Ga., Feb. 22, 2021 /PRNewswire/ — Tris Pharma, Inc. (“Tris”) and Athena Bioscience LLC (“Athena”) announced today that they have entered into an agreement by which Athena received exclusive rights to commercialize a long-acting antihypertensive product developed using  Tris’ proprietary technology. On average, only 50% of adults adhere to chronic […]

VALBIOTIS Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021

The first subject, with blood LDL-cholesterol (“bad cholesterol”) levels greater than 130 mg/dL, has undergone the initial medical examination for the HEART protocol on the active substance TOTUM-070. The HEART study will include 120 people with elevated blood LDL-cholesterol, a risk factor for cardiovascular disease and the primary endpoint of […]

Study Confirms Elucid’s AI Software Accurately Estimates Lesion-Specific Ischemia Compared to Standard of Care

BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, announced today the publication of new clinical data in the International Journal of Cardiology. The study, entitled “Coronary plaque assessment of Vasodilative capacity by CT angiography effectively estimates fractional flow reserve” demonstrates that Fractional Flow Reserve (FFR) […]

Medtronic Announces Voluntary Recall of Unused Valiant Navion™ Thoracic Stent Graft System

DUBLIN, Feb. 17, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™ thoracic stent graft system and informed physicians to immediately cease use of the device until further notice. In accordance with its commitment to patient safety – […]

Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)

Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a) 17 February 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics […]

Shockwave Intravascular Lithotripsy FDA Approved to Treat Advanced Heart Disease

Transformative Technology Now Available for Calcified Coronary Plaque SANTA CLARA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company’s sonic pressure wave therapy received Pre-Market Approval for […]

Dr. Sanjay Rajagopalan Recognized With American College of Cardiology Top Honor

Rajagopalan to be presented with the Distinguished Scientist Award – Translational Domain during ACC’s 70th Annual Scientific Session CLEVELAND — Sanjay Rajagopalan, MD, FACC, has been awarded the 2021 Distinguished Scientist Award – Translational Domain by the American College of Cardiology (ACC) for his contributions to the cardiovascular profession. Dr. […]

Windtree Announces Issuance of New U.S. Patent Covering Technology on Its Redesigned AEROSURF® Device

New patent covers updated aerosol delivery system and design until 2039 WARRINGTON, Pa., Feb. 16, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that the United States Patent and Trademark Office (USPTO) […]

Heart Valve Disease Awareness Day Campaign Celebrates Fifth Anniversary with Focus on Health Disparities

Advocates Continue to Drive Forward Heart Valve Disease Awareness, While Highlighting the Inequities in Risk Factors, Diagnosis, and Treatment Faced by Black Americans WASHINGTON, Feb. 16, 2021 /PRNewswire/ — On Monday, February 22, more than 90 national organizations and thousands of patient advocates will recognize the fifth anniversary of the annual HVD Awareness Day (“Valve Disease […]

Orsini Specialty Pharmacy Selected To Be The Exclusive Specialty Pharmacy Partner For Evkeeza™ (evinacumab-dgnb)

ELK GROVE VILLAGE, Ill., Feb. 16, 2021 /PRNewswire/ — Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Regeneron Pharmaceuticals, Inc. as the exclusive specialty pharmacy partner for EvkeezaTM (evinacumab-dgnb). Evkeeza is approved by the U.S. Food and Drug Administration (FDA) as an adjunct […]